Evidence map›Paper›PMID 23857459›Full record

Observational studyEuropean journal of nuclear medicine and molecular imaging2014

Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.

Carlos Salgado Garcia, Carlos Salgado Garcia, Amelia Jimenez Heffernan, Amelia Jimenez Heffernan, Elena Sanchez de Mora, Carlos Ramos Font, Juana Lopez Martin, Francisco Rivera de los Santos, Ignacio Ynfante Milá

Erratum issuedAbstract readComparative StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017
    Trial
  2. Article
  3. Review
  4. Safety of regadenoson stress testing in patients with pulmonary hypertension.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018
    Article
  5. Observational
  6. Article
  7. Review
  8. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.International journal of chronic obstructive pulmonary disease · 2014
    Review
4 · The record

Corrections and comments

  • Erratum issued
    Garcia, Carlos Salgado [corrected to Salgado Garcia, Carlos]; Heffernan, Amelia Jimenez]
5 · Who and what money

Authors and funding

9 authors.

Carlos Salgado Garcia
Carlos Salgado GarciaDepartment of Nuclear Medicine, Hospital Juan Ramon Jimenez, Ronda Norte, s/n, 21005, Huelva, Spain, carlos.salgado.garcia@gmail.com.
Amelia Jimenez Heffernan
Amelia Jimenez Heffernan
Elena Sanchez de Mora
Carlos Ramos Font
Juana Lopez Martin
Francisco Rivera de los Santos
Ignacio Ynfante Milá

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the safety of regadenoson, a selective agonist of A2A adenosine receptors, combined with low-level exercise, between subjects with mild/moderate chronic obstructive pulmonary disease (COPD) and asthma referred for myocardial perfusion imaging (MPI).

methodsWe studied 116 patients, of whom 67 had COPD and 49 asthma (62 % men, mean age 68.3 ± 11.3 years, range 31 - 87 years). Patient demographics, past medical history, medications, clinical symptoms during stress and changes in blood pressure (BP) and heart rate (HR) were evaluated.

resultsBoth groups were comparable with regard to hypertension, dyslipidaemia, diabetes and medications with the exception of a higher rate of use of anticholinergics in patients with COPD and of antileukotrienes in asthmatics (58.2 % vs. 28.6 % and 1.5 % vs. 14.3 %, respectively; all p < 0.01). There was a higher incidence of dyspnoea in COPD patients and of headache and feeling hot in asthmatic patients (40.3 % vs. 22.4 %, 6 % vs. 18.4 % and 10.4 % vs. 26.5 %, respectively; all p < 0.05). Although there was no difference in the incidence of other adverse events, we observed a higher frequency in asthmatics of flushing, dry mouth, sweating and fatigue (1.5 % vs. 6.1 %, 14.9 % vs. 24.5 %, 0 % vs. 4.1 % and 37.3 % vs. 49 %, respectively). Adverse events were self-limiting, except in three patients who suffered persistent dyspnoea (2 of 67 COPD patients; 1 of 49 asthma patients) requiring theophylline administration. We observed no significant changes in BP among either group, but there was a tendency towards a higher increase in systolic BP in COPD patients following regadenoson administration (148.3 ± 27.6 vs. 154.6 ± 31.0 mmHg, p = 0.056).

conclusionThis study showed a good safety profile in our series of COPD and asthma patients undergoing MPI. Regadenoson was well tolerated by all patients, with dyspnoea, headache and feeling hot showing differences between groups.

Indexed as

SafetyAdultAgedAged, 80 and overAsthmaBlood PressureExercise TestFemaleHeart RateHumansMaleMiddle AgedPulmonary Disease, Chronic ObstructivePurinesPyrazolesStress, PhysiologicalPurinesPyrazolesregadenoson

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.